SciELO - Scientific Electronic Library Online

 
vol.32 número1Frecuencia y factores asociados al retraso en el tratamiento del cáncer de mama en Brasil, según datos del Panel de Oncología, 2019-2020Prevalencia de salud cardiovascular ideal en la población adulta brasileña - Encuesta Nacional de Salud 2019 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Epidemiologia e Serviços de Saúde

versión impresa ISSN 1679-4974versión On-line ISSN 2237-9622

Resumen

FULONE, Izabela; SILVA, Marcus Tolentino  y  LOPES, Luciane Cruz. Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017. Epidemiol. Serv. Saúde [online]. 2023, vol.32, n.1, e2022556.  Epub 13-Mar-2023. ISSN 1679-4974.  http://dx.doi.org/10.1590/s2237-96222023000300015.

Objective:

to investigate sociodemographic and clinical characteristics of users of atypical antipsychotics receiving care via the Specialized Component of Pharmaceutical Assistance (Componente Especializado da Assistência Farmacêutica - CEAF), for the treatment of schizophrenia in Brazil, between 2008 and 2017.

Methods:

this was a retrospective cohort study using records of the authorizations for high complexity procedures retrieved from the Outpatient Information System of the Brazilian National Health System, from all Brazilian states.

Results:

of the 759,654 users, 50.5% were female, from the Southeast region (60.2%), diagnosed with paranoid schizophrenia (77.6%); it could be seen a higher prevalence of the use of risperidone (63.3%) among children/adolescents; olanzapine (34.0%) in adults; and quetiapine (47.4%) in older adults; about 40% of children/adolescents were in off-label use of antipsychotics according to age; adherence to CEAF was high (82%), and abandonment within six months was 24%.

Conclusion:

the findings expand knowledge about the sociodemographic and clinical profile of users and highlight the practice of off-label use.

Palabras clave : Antipsychotics; Brazilian National Health System; Schizophrenia; Brazil; Off-Label Use; Cohort Studies.

        · resumen en Español | Portugués     · texto en Inglés | Portugués     · Inglés ( pdf ) | Portugués ( pdf )